Results 151 to 160 of about 8,958 (210)

Optimizing Oncolytic Virotherapy for Malignant Glioma: From Bench to Bedside. [PDF]

Cancer Manag Res
Jiang W, Tian Y, Gu H, Guan W.
europepmc   +1 more source

Oncolytic virotherapy -in vivo veritas

Oncotarget, 2018
Kemler, Iris, Neuhauser, Claudia, Dingli, David   +2 more
openaire   +2 more sources

Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8⁺ T cells. [PDF]

J Immunother Cancer
Yang Y, He J, Liang T, Li K, Lin Y, Wang H, Xi W, Ye S, Qiu D, Xie C, Hao Y, Li T, Yue S, Ye L, Chen X.   +14 more
europepmc   +1 more source

The Evolution, Current Landscape, and Future Prospects of Oncolytic Virotherapy in Melanoma: Talimogene Laherparepvec and Beyond. [PDF]

Cells
Smestad J, Rieth J, Laux D, Milhem M.
europepmc   +1 more source

Editorial: Oncolytic virotherapy, volume II. [PDF]

Front Mol Biosci
Al-Shammari AM, Piccaluga PP.
europepmc   +1 more source

Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity. [PDF]

J Immunother Cancer
Hayes AJ, Davies EJ, Wilkinson M, Smith HG, Nenclares P, Lund T, Larkeryd A, Appleton E, Patin EC, Pedersen M, Rullan A, Mohamed HS, Aronson L, Murphy J, Grove L, Mansfield D, Mclaughlin M, Harrington KJ, Melcher A.   +18 more
europepmc   +1 more source

Enhancing oncolytic virotherapy with a tri-specific T-cell engager targeting CD3ε, EpCaM, and 4-1BB: preclinical evaluation and implications for cancer immunotherapy. [PDF]

BMC Med
Dong Z, Zhang H, Zhang H, Bai L, Guo Q, Robinson G, Elalfy A, Liu T, Aimaiti M, Xia X, Zuo S, Zhang Z.   +11 more
europepmc   +1 more source

Oncolytic virotherapy mobilizes tumor-resident, granzyme B-producing bystander CD4⁺ T cells to inhibit systemic microbial infection. [PDF]

Mol Ther Oncol
Yue S, He J, Ye S, Lin Y, Yang Y, Hao Y, Liang T, Qiu D, Li K, Xie C, Wang H, Xi W, Yang X, Xiong Y, Xu Y, Xu W, Yang Y, Zhang G, Zhao J, Ye L, Li M, Chen X.   +21 more
europepmc   +1 more source

Extended Survival in a Dog with Primary Bone Hemangiosarcoma Following Treatment with Neoadjuvant Oncolytic Virotherapy and Standard of Care. [PDF]

Vet Sci
Labé C, Chehadeh A, Winter A, Pracht S, Stuebner KM, Lewellen M, Eskander B, O'Sullivan MG, Tabaran AF, Ober C, Henson MS, Seelig D, Russell SJ, Modiano JF, Naik S, Makielski KM.   +15 more
europepmc   +1 more source